Short answer: guidelines call for two morning testosterone tests to confirm the diagnosis, plus baseline hematocrit and (when indicated) PSA/prostate exam — then ongoing hematocrit, testosterone, PSA, and symptom checks for as long as you stay on therapy.
TRT isn't a start-and-forget treatment — it comes with a defined schedule of labs, both before you start and for as long as you're on it. Here's what the Endocrine Society and American Urological Association guidelines actually call for, and why each check matters.
Confirming the Diagnosis
Before treatment starts, guidelines call for confirming low testosterone with two separate measurements — same lab, same assay — drawn in the early morning, since testosterone follows a daily rhythm and peaks around that time.[1]A single test isn't considered sufficient to diagnose hypogonadism.
Baseline Labs Before You Start
Beyond confirming low testosterone itself, two other baseline checks matter:
- Hematocrit— checked at baseline to confirm it's below 50%. Men who start with elevated hematocrit face a higher risk of crossing the treatment safety threshold once therapy begins.[1]
- PSA and prostate exam — for men 40 and older with a baseline PSA above 0.6 ng/mL, a digital rectal exam and PSA measurement are recommended before starting treatment.[1]
Checking That Testosterone Reaches the Target Range
Once treatment starts, testosterone levels are typically rechecked 3 to 6 months in, with the goal of landing in the mid-normal range.[1] Exactly when and how that check happens depends on the delivery method:
- Injectable (enanthate/cypionate): measured midway between injections, with dose or frequency adjusted if levels run above roughly 700 ng/dL or below roughly 400 ng/dL.[1]
- Transdermal gel: checked 2 to 8 hours after application, after at least one week of treatment.[3]
- Transdermal patch: checked 3 to 12 hours after application.[3]
- Pellets: checked at the end of the dosing interval.[3]
Hematocrit: The Most Important Ongoing Safety Check
Hematocrit gets rechecked at 3 to 6 months after starting, then annually for as long as therapy continues.[1] This is the single most important recurring safety check with TRT, since elevated red blood cell count is the most common side effect of treatment.
If hematocrit rises above 54%: guidelines are explicit that testosterone therapy should be paused until levels come back down, the patient should be evaluated for hypoxia and sleep apnea, and therapy should only restart at a reduced dose.[1]
Ongoing Prostate Monitoring
Guidelines recommend a digital rectal exam and PSA check 3 to 12 months after starting treatment for men aged 55 to 69, and for men 40 to 69 at increased prostate cancer risk who choose to undergo monitoring.[1] A peer-reviewed study measuring real-world PSA changes on testosterone therapy supports this same timing — checking at 3 and 12 months in hypogonadal men over 50.[4] Specific thresholds trigger a urology referral: a PSA rise of more than 1.4 ng/mL within any 12-month period, a confirmed PSA above 4 ng/mL at any point, or a prostate abnormality found on exam.[1] For men without a personal history of prostate cancer, the AUA frames PSA testing as a shared decision between patient and provider, rather than something mandated for everyone starting TRT.[5]
Beyond the Labs: How You're Actually Doing
Labs aren't the whole picture. Guidelines also call for a clinical check-in at 3 to 12 months after starting, then annually, to assess whether symptoms have actually improved and whether any side effects have shown up.[2]The AUA's more recent guideline adds a specific recommendation worth knowing: if testosterone has normalized on lab testing by 3 to 6 months but symptoms haven't meaningfully improved, that's a reasonable point to discuss stopping treatment altogether rather than continuing indefinitely.[5]
Where the Two Major Guidelines Line Up
The AUA's guideline broadly agrees with the Endocrine Society framework, though it frames the ongoing monitoring cadence as expert opinion rather than graded clinical trial evidence — recommending testosterone rechecks every 6 to 12 months once therapeutic levels are established, to confirm levels stay in range.[6] The overall picture from both guidelines is consistent: confirm the diagnosis carefully, check hematocrit and PSA at baseline, verify testosterone response early, then settle into a routine of periodic hematocrit, PSA, and symptom checks for the duration of treatment.
A provider who's vague about this monitoring schedule, or who skips baseline hematocrit and PSA altogether, is cutting corners on real safety infrastructure — compare how thoroughly labs are handled on RENVA's Men's Health / TRT hub before choosing one.
Sources
- Testosterone Therapy in Men with Androgen Deficiency Syndromes — Clinical Practice Guideline — Endocrine Society (via University of Louisville Endocrinology reading list) louisville.edu
- Diagnosis, Treatment, and Follow-up of Men with Androgen Deficiency — Endocrine Society endocrine.org
- Recommendations for Monitoring of Men Receiving Testosterone Therapy — NCBI Bookshelf (National Institutes of Health) ncbi.nlm.nih.gov
- Prostate-Specific Antigen Concentrations in Response to Testosterone Therapy — PMC (National Institutes of Health) pmc.ncbi.nlm.nih.gov
- Evaluation and Management of Testosterone Deficiency: AUA Guideline — American Urological Association auanet.org
- Table 7: Follow-up Laboratory Testing — American Urological Association auanet.org
Frequently Asked Questions
What labs do I need before starting TRT?
Two confirmed morning testosterone measurements, baseline hematocrit (should be below 50%), and — for men 40+ with elevated PSA — a baseline PSA test and digital rectal exam.[1]
How often is hematocrit checked once I'm on TRT?
At baseline, again at 3 to 6 months, then annually for the duration of treatment. If it rises above 54%, therapy is paused until it comes back down.[1]
Do I need regular prostate screening on TRT?
Guidelines recommend PSA and prostate exams at 3–12 months for men 55–69, and for higher-risk men 40–69 who opt in — but PSA testing for average-risk men is framed as a shared decision, not a universal requirement.[5]
What happens if my testosterone doesn't reach the target range?
Dose or injection frequency is typically adjusted based on levels measured midway between injections (for injectables) — the goal is landing in the mid-normal range by 3 to 6 months.[1]